1. Generics Bulletin
  2. >>Legal & IP

Unsealed US Price-Fixing Complaint Reveals ‘Diary Of Collusion’

Excerpts From Notebook Detailing Alleged Anti-Competitive Conduct Published

 
• By Dave Wallace

Fresh details have been revealed in the ongoing saga of US generic price-fixing litigation, with a newly-published unredacted complaint disclosing excerpts from a notebook alleged to contain details of anti-competitive conduct.

Red Diary Book Lock
Excerpts from a so-called ‘Diary of Collusion’ have been revealed • Source: Shutterstock

The latest development in the ongoing saga of US generic price-fixing litigation has seen excerpts published from a notebook that allegedly contains details of anti-competitive agreements between various generics firms, recorded by a sales executive who is co-operating with the investigation.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.